WO2025031282 - RNAI AGENT TARGETING FXI, PREPARATION METHOD THEREFOR, AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/031282
Publication Date
13.02.2025
International Application No.
PCT/CN2024/109455
International Filing Date
02.08.2024
Title **
[English]
RNAI AGENT TARGETING FXI, PREPARATION METHOD THEREFOR, AND USE THEREOF
[French]
AGENT ARNI CIBLANT FXI, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
一种靶向FXI的RNAi剂、其制备方法及用途
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
WU, Junjun
JIANG, Wenjuan
WEI, Qingzhu
XIAO, Ying
CHEN, Dushen
LI, Jiani
LU, Yinsuo
HONG, Zexin
Priority Data
202310978452.6
04.08.2023
CN
202311113168.9
31.08.2023
CN
202311228492.5
21.09.2023
CN
202311581109.4
22.11.2023
CN
202311807430.X
22.12.2023
CN
202410877247.5
01.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1850 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 2001 | |
| South Korea | Filing, Examination, Granting | 1969 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,136
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are an RNAi agent targeting FXI, a preparation method therefor, and a use thereof. The present application also relates to a use of the RNAi agent and a pharmaceutical composition comprising the RNAi agent in the prevention or treatment of FXI-related diseases, in particular thrombosis-related diseases.[French]
L'invention concerne un agent ARNi ciblant FXI, son procédé de préparation et son utilisation. La présente invention concerne également une utilisation de l'agent ARNi et une composition pharmaceutique comprenant l'agent ARNi pour la prévention ou le traitement de maladies associées à FXI, en particulier de maladies liées à la thrombose.[Chinese]
提供一种靶向FXI的RNAi剂、其制备方法及用途，还涉及RNAi剂以及包含所述RNAi剂的药物组合物用于预防或治疗与FXI相关疾病中的用途，优选自血栓相关疾病。